ArcticZymes Technologies Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 1/6
ArcticZymes Technologies has been growing earnings at an average annual rate of 20.9%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 14.5% per year. ArcticZymes Technologies's return on equity is 6.1%, and it has net margins of 15.6%.
Key information
20.9%
Earnings growth rate
20.8%
EPS growth rate
| Biotechs Industry Growth | 20.9% |
| Revenue growth rate | 14.5% |
| Return on equity | 6.1% |
| Net Margin | 15.6% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 08
ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
Feb 02ArcticZymes Technologies ASA's (OB:AZT) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Apr 29Downgrade: Here's How This Analyst Sees ArcticZymes Technologies ASA (OB:AZT) Performing In The Near Term
Apr 15One Analyst Just Shaved Their ArcticZymes Technologies ASA (OB:AZT) Forecasts Dramatically
Jan 13Here's What Analysts Are Forecasting For ArcticZymes Technologies ASA (OB:AZT) After Its First-Quarter Results
May 01What ArcticZymes Technologies ASA's (OB:AZT) P/E Is Not Telling You
Oct 28A Look At The Fair Value Of ArcticZymes Technologies ASA (OB:AZT)
Jul 26I Ran A Stock Scan For Earnings Growth And ArcticZymes Technologies (OB:AZT) Passed With Ease
Apr 28Can You Imagine How Elated ArcticZymes Technologies' (OB:AZT) Shareholders Feel About Its 992% Share Price Gain?
Mar 17Is Weakness In ArcticZymes Technologies ASA (OB:AZT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Jan 31
What Percentage Of ArcticZymes Technologies ASA (OB:AZT) Shares Do Insiders Own?
Jan 05Are ArcticZymes Technologies's (OB:AZT) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 01Revenue & Expenses BreakdownBeta
How ArcticZymes Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 120 | 19 | 59 | 0 |
| 30 Sep 23 | 119 | 18 | 60 | 0 |
| 30 Jun 23 | 118 | 14 | 63 | 0 |
| 31 Mar 23 | 120 | 17 | 63 | 0 |
| 31 Dec 22 | 138 | 33 | 61 | 0 |
| 30 Sep 22 | 150 | 47 | 59 | 0 |
| 30 Jun 22 | 147 | 52 | 52 | 0 |
| 31 Mar 22 | 139 | 48 | 52 | 0 |
| 31 Dec 21 | 131 | 46 | 48 | 0 |
| 30 Sep 21 | 114 | 68 | 45 | 0 |
| 30 Jun 21 | 108 | 67 | 43 | 0 |
| 31 Mar 21 | 120 | 84 | 37 | 0 |
| 31 Dec 20 | 98 | 74 | 35 | 0 |
| 30 Sep 20 | 64 | 43 | 27 | 0 |
| 30 Jun 20 | 68 | 37 | 29 | 0 |
| 31 Mar 20 | 88 | 8 | 46 | 0 |
| 31 Dec 19 | 49 | -1 | 34 | 0 |
| 30 Sep 19 | 80 | -9 | 49 | 0 |
| 30 Jun 19 | 79 | -10 | 47 | 0 |
| 31 Mar 19 | 73 | -13 | 47 | 0 |
| 31 Dec 18 | 73 | -14 | 46 | 0 |
| 30 Sep 18 | 70 | -20 | 49 | 0 |
| 30 Jun 18 | 63 | -27 | 50 | 0 |
| 31 Mar 18 | 69 | -27 | 51 | 0 |
| 31 Dec 17 | 73 | -25 | 52 | 0 |
| 30 Sep 17 | 74 | -26 | 59 | 0 |
| 30 Jun 17 | 80 | -24 | 58 | 0 |
| 31 Mar 17 | 79 | -21 | 57 | 0 |
| 31 Dec 16 | 79 | -20 | 57 | 0 |
| 30 Sep 16 | 78 | -20 | 53 | 0 |
| 30 Jun 16 | 72 | -19 | 51 | 0 |
| 31 Mar 16 | 66 | -18 | 49 | 0 |
| 31 Dec 15 | 59 | -17 | 47 | 0 |
| 30 Sep 15 | 55 | -15 | 42 | 0 |
| 30 Jun 15 | 48 | -16 | 41 | 0 |
| 31 Mar 15 | 46 | -18 | 39 | 0 |
| 31 Dec 14 | 38 | -22 | 38 | 0 |
| 30 Sep 14 | 34 | -23 | 38 | 0 |
| 30 Jun 14 | 31 | -21 | 37 | 0 |
| 31 Mar 14 | 26 | -24 | 37 | 0 |
| 31 Dec 13 | 28 | -23 | 38 | 0 |
| 30 Sep 13 | 29 | -23 | 33 | 0 |
| 30 Jun 13 | 26 | -25 | 33 | 0 |
Quality Earnings: AZT has a high level of non-cash earnings.
Growing Profit Margin: AZT's current net profit margins (15.6%) are lower than last year (23.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AZT has become profitable over the past 5 years, growing earnings by 20.9% per year.
Accelerating Growth: AZT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AZT had negative earnings growth (-43%) over the past year, making it difficult to compare to the Biotechs industry average (-2.3%).
Return on Equity
High ROE: AZT's Return on Equity (6.1%) is considered low.